Clinical Trial Detail

NCT ID NCT03420508
Title Treating Patients With Melanoma and ALK Alterations With Ensartinib
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

melanoma

Therapies

Ensartinib

Age Groups: adult senior

Additional content available in CKB BOOST